Les cancers papillaires de la thyroïde (PTC) sont les tumeurs endocrines les plus courantes et représentent 2-3% de tous les cancers humains. Les altérations génétiques les plus pertinentes trouvées dans ces tumeurs sont des mutations dans les gènes BRAF et RAS, et des translocations du gène RET. Ces translocations oncogéniques, connues sous le nom de RET/PTC, résultent de la fusion de RET avec des gènes partenaires non-apparentés. L’exposition aux radiations ionisantes est le facteur de risque le plus important pour la formation de RET/PTC. Durant ces dernières années, notre groupe a mis en évidence un rôle crucial des espèces réactives de l'oxygène (ROS) dans la formation de RET/PTC dans des cellules thyroïdiennes in vitro et a notamment montré que l'irradiation (IR) induit l’établissement d’un stress oxydatif persistant du aux ROS produites par la NADPH Oxydase DUOX1, laquelle est induite à post-IR. Cela conduit à des dommages à l'ADN. Les enfants présentent un risque significativement plus élevé de développer des cancers radio-induits de la thyroïde exprimant RET/PTC, probablement en raison du taux de prolifération élevé des cellules. Ceci suggère que la dynamique de réplication pourrait être impliquée dans la formation de la translocation RET/PTC1. En effet, il a été montré que l'induction pharmacologique d’un stress réplicatif peut favoriser la formation de RET/PTC in vitro dans les cellules thyroïdiennes. Ainsi, pour déterminer si un stress réplicatif peut contribuer aux effets à long terme de l'irradiation: à savoir une persistance des lésions de l'ADN et la formation de RET/PTC1, nous avons analysé les effets à post-IR dans les cellules NTHY-ori3.1. Nos résultats confirment qu’une irradiation des cellules aux rayons X à la dose de 5 Gy induit deux vagues de stress oxydatif: une première vague forte mais transitoire qui se produit dans les minutes qui suivent l'irradiation et une deuxième vague dont l’ augmentation débute 2 jours après l'irradiation pour persister ensuite. Ces deux pics de stress oxydatif conduisent à deux pics de dommages à l'ADN. L'irradiation des cellules à cette dose n’a aucun effet sur la prolifération et sur la progression du cycle cellulaire. Cependant, plusieurs marqueurs de stress réplicatif sont exprimés trois jours après l'irradiation. Par ailleurs, l'analyse de la dynamique de réplication révèle une diminution de la vitesse de réplication à post-IR qui est contrecarrée par les antioxydants, suggérant qu’un stress oxydatif peut contribuer à un stress réplicatif. Enfin, par ChIP-QPCR, nous observons que les gènes impliqués dans RET/PTC1 présentent plus de cassures double brin que des gènes endogènes, et ce, trois jours après l'irradiation. Ainsi, nous proposons qu’un stress réplicatif induit par un stress oxydatif pourrait être potentiellement impliqué dans l'étiologie des tumeurs RET/PTC-positives. / Papillary thyroid cancers (PTC) are the most common endocrine tumors and account for 2-3% of all human cancers. The most relevant genetic alterations found in these tumors are mutations in the genes BRAF and RAS, and chromosomal translocations in RET, a proto-oncogene activated in 15-20% of PTCs. These oncogenic translocations, known as RET/PTCs, result from the fusion of RET with unrelated partner genes. Ionizing radiation is a major risk factor for RET/PTC formation, however, the molecular mechanisms involved in these radioinduced translocations just begun to be unveiled. In the past few years, our group has reported a critical role for reactive oxygen species (ROS) in the formation of RET/PTC in thyroid cells in vitro and has also shown that irradiation can elicit a persistent oxidative stress caused by the upregulation of the NADPH Oxidase DUOX1 that leads to DNA damage, mediating at least part of the effects of radiation. However, how could ROS lead to the formation of RET/PTC is not fully understood. Children are at significantly higher risk of developing radio-induced thyroid tumors, specially RET/PTC positive, probably due to the intense proliferation rate of their follicular thyroid cells. This epidemiological observation prompts the assumption that replication dynamics may be involved in RET/PTC formation. Indeed, it has been shown that the pharmacological induction of replicative stress can stimulate the in vitro formation of RET/PTC in thyroid cells. Thus, to investigate whether replicative stress might contribute for the long-term effects of irradiation on DNA damage and RET/PTC formation, we analyzed the effects of radiation in NTHY-ori3.1 thyroid cell lineage in terms of oxidative and replicative stress and replication dynamics. Our results confirm that irradiation triggers two waves of oxidative stress: first, a strong but transient oxidative burst takes place minutes after irradiation and next, a persistently increased oxidative stress that starts only 2 days after irradiation. These two peaks of oxidative stress lead to two peaks of DNA damage. Irradiation caused little or no effect on proliferation nor on cell cycle progression. However, several protein markers of replicative stress, such as pATR, pATM, pChk1 and pRPA are induced three days after irradiation. Moreover, replication dynamics analysis revealed a diminished replication speed that has been reversed by antioxidants, suggesting that oxidative stress may contribute to replication defects. Finally, using ChIP-qPCR, we observed that the genes involved in RET/PTC1 translocation present more double-stranded breaks than RET/PTC-unrelated genes 3 days after irradiation. Hence, we propose that replicative stress is potentially involved in the etiology of RET/PTC-positive tumors. / HECHT, Fabio. The role of reactive oxygen species in thyroid radio-carcinogenesis. Rio de Janeiro, 2018. Doctoral thesis - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil and Université Paris-Saclay, Orsay, France, 2018.O câncer papilífero de tireoide é o tumor endócrino mais comum e corresponde a 2-3% de todos os cânceres humanos. As alterações genéticas mais relevantes relacionadas a esse tumor são mutações nos genes BRAF e RAS e translocações do gene RET, um proto-oncogene ativado em 15-20% dos tumores papilíferos. Essas translocações, conhecidas como RET/PTC, resultam da fusão de RET com diversos outros genes. A radiação ionizante é um importante fator de risco para a formação de RET/PTC, no entanto, o mecanismo molecular responsável por essa translocação radioinduzida ainda não foi elucidado. Nos últimos anos, nosso grupo demonstrou um papel crítico exercido pelas espécies reativas de oxigênio na formação de RET/PTC em células tireoidianas in vitro e também mostrou que a irradiação promove um estresse oxidativo persistente causado pelo aumento de expressão da NADPH Oxidase DUOX1, levando à dano ao DNA, mediando assim parte dos efeitos da radiação. No entanto, como o ROS leva à formação de RET/PTC ainda não é compreendido. Crianças possuem um risco significativamente mais alto de desenvolver tumores tireodianos após a irradiação, especialmente RET/PTC positivos, provavelmente em função da intensa proliferação das células tireodianas. Essa associação sugere que a replicação esteja envolvida na formação de RET/PTC. De fato, foi observado que a indução farmacológica de estresse replicativo pode estimular a formação in vitro de RET/PTC em células tireodianas. Portanto, para investigar se o estresse replicativo contribui com os efeitos da irradiação no longo prazo sobre o dano ao DNA e formação de RET/PTC, nós investigamos o papel da radiação sobre o estresse oxidativo e replicativo, além da dinâmica de replicação de linhagem de células tireodianas NTHY-ori 3.1. Nossos resultados confirmam que a irradiação desencadeia duas ondas de estresse oxidativo: primeiramente, um forte, mas transitório pico de espécies reativas de oxigênio é observado minutos após a irradiação, seguido por um novo e persistente pico que só é observado a partir de dois dias após a irradiação. Esses dois picos de estresse oxidativo resultam em dois picos de dano ao DNA. A irradiação causou pouco ou nenhum efeito na proliferação ou na progressão do ciclo celular. No entanto, vários marcadores de estresse replicativo foram observados três dias após a irradiação, como pATR, pATM, pChk1 e pRPA. Além disso, a análise da dinâmica de replicação mostrou uma diminuição na velocidade da replicação que foi revertida por antioxidantes, sugerindo que o estresse oxidativo contribui para distúrbios dos mecanismos replicativos. Por fim, utilizando ChIP-qPCR, nós observamos que os genes envolvidos na translocação RET/PTC possuem mais quebras duplas do que genes endógenos, dias após a irradiação. Portanto, propomos que o estresse replicativo está potencialmente envolvido na etiologia dos tumores RET/PTC positivos.

Le cancer papillaire de la thyroïde (PTC) est celui le plus fréquent de la thyroïde. Il est caractérisé par des réarrangements chromosomique affectant le gène RET, dont les plus fréquemment observés sont RET/PTC1 et RET/PTC3. Les oncogène de jonction sont spécifiques à la tumeur et représentent une cible privilégiée pour une thérapie ciblée par des petits ARN interférents (siRNA). Notre but est d’introduire une nouvelle approche pharmacologique par siRNA pour les PTC. Pour réaliser nos expériences, la lignée cellulaire humaine PTC, BHP10-3 SCmice exprimant l’oncogène RET/PTC1 a été utilisé. En absence de lignée RET/PTC3 commercialisée nous avons établi la lignée cellulaire RP3 (stablement transfecté la lignée NIH/3T3 issue de fibroblastes de souris par un vecteur d’expression RET/PTC3) qui s’est avérée tumorigène chez la souris. Ensuite, des siRNAs dirigés contre la jonction ont été dessinés. Les siRNAs ont été trouvés efficaces et spécifiques contre leurs propres oncogènes de jonction et ne sont pas capables d'inhiber l'expression de séquences alternées. Les siRNAs ont été vectorisés sous forme de nanoparticules (NPs) de squalène (SQ). In vitro, les NPs siRNA RET/PTC1-SQ et NPs siRNA RET/PTC3-SQ sont incapables d’inhiber l’expression de l’oncogène et l’oncoprotéine sauf transfectés par lipofectamine. Pour cela, un peptide, le GALA-Chol a été combiné aux NPs siRNA RET/PTC1-SQ ce qui les a rendu efficace in vitro dans l’inhibition de l’oncogène et de l’oncoprotéine mais inefficace sur la croissance tumorale in vivo probablement par agrégation des NPs siRNA RET/PTC1-SQ GALA-Chol dans la circulation sanguine. En revanche les NPs siRNA RET/PTC1-SQ (0.5mg/kg/souris) et NPs siRNA RET/PTC3-SQ (2.5mg/kg/souris) sont efficaces in vivo, ils inhibent considérablement la croissance tumorale, réduisent l’expression des oncogènes et des oncoprotéines RET/PTCs, induisent la mort cellulaire par clivage de la caspase-3 et de PARP-1 et restaurent partiellement la différenciation (diminution de marqueur Ki67). Ces résultats suggèrent l'utilisation des NPs siRNAs-SQ en tant que traitement pour les patients atteints de PTC exprimant les oncogènes de jonctions RET/PTCs. / Papillary thyroid carcinoma (PTC) is the most common of thyroid cancers. PTC is characterized by chromosomal rearrangements affecting chromosome 10 and leading to RET/PTC junction oncogenes. The most frequent ones are RET/PTC1 and RET/PTC3. Because the junction oncogenes are present only in the tumour cells, they represent a good target for a specific therapy such as small interfering RNA (siRNA). Our aim is to introduce a new pharmacological approach by siRNA for PTC. To perform the experiments, human BHP10-3 SCmice cell line expressing RET/PTC1 was used. Due to absence of commercially available RET/PTC3 cell line, we established a new RP3 cell line (from NIH/3T3 mouse fibroblasts, transfected stably with the RET/PTC3 expression vector) which was found to become tumorigenic in nude mice. siRNAs were designed within the junction sequences of both RET/PTC1 and RET/PTC3. Both siRNAs were found efficient and specific against their own junction oncogenes and were not able to inhibit the expression of alternate sequences. Then, siRNAs were vectorized in the form of nanoparticles (NPs) of squalene (SQ). In vitro, both siRNA RET/PTC1-SQ NPs and siRNA RET/PTC3-SQ NPs were found to be inefficient in gene and protein inhibitions except once transfected with lipofectamine. Therefore, a peptide GALA-Chol was added in siRNA RET/PTC1-SQ NPs which rendered them efficient in vitro in gene and protein inhibitions but found to be inefficient in vivo. The nanoparticles of siRNA RET/PTC1-SQ NPs (0.5 mg/kg/mouse) and siRNA RET/PTC3-SQ NPs (2.5 mg/kg/mouse) were found to drastically reduce the tumor growth and RET/PTCs oncogene and oncoprotein expressions. Moreover, they induced cell death by cleavage of both caspase-3 and PARP-1 and partially restored differentiation (decrease of Ki67 marker). Our findings highly support the use of siRNAs-SQ NPs as a treatment for patients affected by PTC expressing RET/PTCs.

No câncer, alterações em microRNAs (miRNAs), pequenos RNAs que regulam a tradução protéica, exerce efeito oncogênico (oncomiR). Os oncomiRs regulam genes chave para a proliferação celular e apoptose, sendo importantes para a biologia do câncer. O carcinoma papilífero de tiróide apresenta alterações genéticas alinhadas na via MAPK (RET>RAS>BRAF>ERK). Observamos que a indução do oncogene RET/PTC diminui a expressão de let-7 em células foliculares tiroidianas. Na linhagem TPC-1 (com RET/PTC-1), a introdução de let-7 diminui a proliferação celular e a fosforilaçãode ERK, indicando papel de gene supressor tumoral. No carcinoma anaplásico, avaliamos o papel da introdução do cluster miR-17-92 na linhagem ARO. Observamos que in vitro miR-17-92 atua de forma oncogênica aumentando proliferação e viabilidade celular de ARO. No entanto, estas células apresentam diminuição no crescimento em soft-agar. No xenotransplante, os tumores de ARO-miR-17-92 apresentam menor volume e expressam MMP-9 de forma reduzida, indicando também um papel de gene supressor tumoral para o cluster. / In cancer, alteration in microRNA, small RNAs (~22nt) that regulate post-transcriptionally protein levels, exerts oncogenic role (oncomiR). OncomiRs control genes involved in cell proliferation and apoptosis, influencing cancer biology. Papillary thyroid cancer displays activating genetic alterations in MAPK signaling pathway (RET>RAS>BRAF>ERK). Using conditional induction of oncogenes in thyroid cells, we observed that RET/PTC decreases let-7 miRNA expression. In papillary thyroid cancer cell TPC-1 (with RET/PTC-1) we observed that let-7 introduction inhibits cell proliferation and ERK phosphorylation, indicating tumor suppressor role for let-7. In anaplastic thyroid cancer, we evaluate the role of introduction of miR-17-92 cluster in ARO cell line. We observed in vitro that miR-17-92 increases ARO cell proliferation and viability, acting as oncogene. However, these cells show impaired soft agar growth. In xenotransplant, ARO-miR-17-92 tumors are smaller in volume and express reduced levels of MMP-9, indicating a tumor suppressor role for the cluster.

No câncer, alterações em microRNAs (miRNAs), pequenos RNAs que regulam a tradução protéica, exerce efeito oncogênico (oncomiR). Os oncomiRs regulam genes chave para a proliferação celular e apoptose, sendo importantes para a biologia do câncer. O carcinoma papilífero de tiróide apresenta alterações genéticas alinhadas na via MAPK (RET>RAS>BRAF>ERK). Observamos que a indução do oncogene RET/PTC diminui a expressão de let-7 em células foliculares tiroidianas. Na linhagem TPC-1 (com RET/PTC-1), a introdução de let-7 diminui a proliferação celular e a fosforilaçãode ERK, indicando papel de gene supressor tumoral. No carcinoma anaplásico, avaliamos o papel da introdução do cluster miR-17-92 na linhagem ARO. Observamos que in vitro miR-17-92 atua de forma oncogênica aumentando proliferação e viabilidade celular de ARO. No entanto, estas células apresentam diminuição no crescimento em soft-agar. No xenotransplante, os tumores de ARO-miR-17-92 apresentam menor volume e expressam MMP-9 de forma reduzida, indicando também um papel de gene supressor tumoral para o cluster. / In cancer, alteration in microRNA, small RNAs (~22nt) that regulate post-transcriptionally protein levels, exerts oncogenic role (oncomiR). OncomiRs control genes involved in cell proliferation and apoptosis, influencing cancer biology. Papillary thyroid cancer displays activating genetic alterations in MAPK signaling pathway (RET>RAS>BRAF>ERK). Using conditional induction of oncogenes in thyroid cells, we observed that RET/PTC decreases let-7 miRNA expression. In papillary thyroid cancer cell TPC-1 (with RET/PTC-1) we observed that let-7 introduction inhibits cell proliferation and ERK phosphorylation, indicating tumor suppressor role for let-7. In anaplastic thyroid cancer, we evaluate the role of introduction of miR-17-92 cluster in ARO cell line. We observed in vitro that miR-17-92 increases ARO cell proliferation and viability, acting as oncogene. However, these cells show impaired soft agar growth. In xenotransplant, ARO-miR-17-92 tumors are smaller in volume and express reduced levels of MMP-9, indicating a tumor suppressor role for the cluster.

Adaptor proteins play a vital role in the propagation of cellular signals. Although they lack endogenous catalytic activity, they contain a variety of protein binding modules, which enable them to promote specific and efficient interactions with their binding partners. They form integrative platforms for a variety of molecules (e.g. lipids, tyrosine kinases, cytoskeletal and signaling proteins), and thereby link and coordinate key functions such as cell growth, motility and shape determination. Our laboratory has recently cloned a novel, 130 kDa adaptor protein, named XB130, as a structural homolog of actin-filament-associated-protein (AFAP-110), a stress fiber-binding Src substrate. However, the molecular interactions and functions of this novel adaptor remained to be elucidated. To characterize the function of XB130 we asked two general questions: (1) Is XB130 involved in the signal transduction pathways of tyrosine kinases? And (2) Is XB130 capable of regulating the cytoskeleton and/or is it regulated by the cytoskeleton? To address these questions first we investigated the tissue distribution of XB130 and discovered that it is abundantly expressed in thyroid. Therefore we asked whether it is a target of the thyroid-specific tyrosine kinase, RET/PTC, a genetically rearranged, constitutively active enzyme that plays a pathogenic role in papillary thyroid cancer. We found that XB130 is a RET/PTC substrate that couples RET/PTC signaling to phosphatidylinositol 3-kinase (PI3K) activation through its phosphorylation dependent interaction with the regulatory subunit p85 of PI3K. XB130 plays an important role in PI3K signaling, as downregulation of XB130 in TPC1 papillary thyroid cancer cells, harboring the RET/PTC1 kinase, strongly reduced Akt activity and concomitantly inhibited cell cycle progression and survival in suspension. In the second part we demonstrate that XB130 is a novel Rac- and cytoskeleton-regulated protein that exhibits high affinity to lamellipodial (branched) F-actin and impacts motility and invasiveness of tumor cells. In conclusion, my work characterized a novel adaptor protein and assigned two well-defined pathophysiological functions to it in the context of thyroid cancer cells.

Adaptor proteins play a vital role in the propagation of cellular signals. Although they lack endogenous catalytic activity, they contain a variety of protein binding modules, which enable them to promote specific and efficient interactions with their binding partners. They form integrative platforms for a variety of molecules (e.g. lipids, tyrosine kinases, cytoskeletal and signaling proteins), and thereby link and coordinate key functions such as cell growth, motility and shape determination. Our laboratory has recently cloned a novel, 130 kDa adaptor protein, named XB130, as a structural homolog of actin-filament-associated-protein (AFAP-110), a stress fiber-binding Src substrate. However, the molecular interactions and functions of this novel adaptor remained to be elucidated. To characterize the function of XB130 we asked two general questions: (1) Is XB130 involved in the signal transduction pathways of tyrosine kinases? And (2) Is XB130 capable of regulating the cytoskeleton and/or is it regulated by the cytoskeleton? To address these questions first we investigated the tissue distribution of XB130 and discovered that it is abundantly expressed in thyroid. Therefore we asked whether it is a target of the thyroid-specific tyrosine kinase, RET/PTC, a genetically rearranged, constitutively active enzyme that plays a pathogenic role in papillary thyroid cancer. We found that XB130 is a RET/PTC substrate that couples RET/PTC signaling to phosphatidylinositol 3-kinase (PI3K) activation through its phosphorylation dependent interaction with the regulatory subunit p85 of PI3K. XB130 plays an important role in PI3K signaling, as downregulation of XB130 in TPC1 papillary thyroid cancer cells, harboring the RET/PTC1 kinase, strongly reduced Akt activity and concomitantly inhibited cell cycle progression and survival in suspension. In the second part we demonstrate that XB130 is a novel Rac- and cytoskeleton-regulated protein that exhibits high affinity to lamellipodial (branched) F-actin and impacts motility and invasiveness of tumor cells. In conclusion, my work characterized a novel adaptor protein and assigned two well-defined pathophysiological functions to it in the context of thyroid cancer cells.

No description available.

No description available.

Neste estudo, geramos ensaios de espectrometria de massa para detecção de 111 mutações nos genes RET, BRAF, NRAS, HRAS, KRAS, PIK3CA e AKT1 e avaliamos inúmeras linhagens celulares e tumores tiroidianos. Mostramos que as mutações dos genes BRAF e RAS refletem prognósticos distintos e que as mutações BRAF são altamente prevalentes em câncer metastático. Mutações dos genes PIK3CA e AKT1, esta última sendo reportada pela primeira vez no câncer de tiróide, são relativamente frequentes neste câncer. Avaliamos ainda a função do microRNA let-7 neste câncer. Mostramos que a ativação do rearranjo RET/PTC3 em células de tiróide PCCl3 reduz a expressão de let-7. Além disso, a transfecção deste microRNA em células TPC-1, que apresentam o rearranjo RET/PTC1, inibe a fosforilação de ERK, o crescimento celular e modula a expressão de genes do ciclo celular e diferenciação. Estes dados contribuem na aplicação de terapias dirigidas a efetores das vias PI3K e MAPK no câncer de tiróide, além de salientar o envolvimento do miRNA let-7 como um gene supressor tumoral nesta doença. / In this study, we designed an assay panel for genotyping 111 mutations by mass spectrometry in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1 and other related genes in many thyroid cancer cell lines and tumors. We show that patients with BRAF and RAS mutations have distinct prognosis and that BRAF mutations are highly prevalent in metastatic thyroid cancers. Mutations of PIK3CA and AKT1, the latter not previously described in this disease, are comparatively frequent in thyroid cancers. In addition, we evaluated the role of let-7 microRNA in this cancer. We show that RET/PTC3 activation in PCCl3 thyroid cells reduces let-7 expression. Moreover, transfection of let-7 in TPC-1 cells, which harbor RET/PTC1 rearrangement, inhibits MAPK activation, reduces cell growth and modulates the expression of cell cycle and differentiation genes. These findings may contribute to the design of therapies directed at MAPK and PI3K effectors and to highlight the function of let-7 as tumor suppressor gene in thyroid cancer.

Neste estudo, geramos ensaios de espectrometria de massa para detecção de 111 mutações nos genes RET, BRAF, NRAS, HRAS, KRAS, PIK3CA e AKT1 e avaliamos inúmeras linhagens celulares e tumores tiroidianos. Mostramos que as mutações dos genes BRAF e RAS refletem prognósticos distintos e que as mutações BRAF são altamente prevalentes em câncer metastático. Mutações dos genes PIK3CA e AKT1, esta última sendo reportada pela primeira vez no câncer de tiróide, são relativamente frequentes neste câncer. Avaliamos ainda a função do microRNA let-7 neste câncer. Mostramos que a ativação do rearranjo RET/PTC3 em células de tiróide PCCl3 reduz a expressão de let-7. Além disso, a transfecção deste microRNA em células TPC-1, que apresentam o rearranjo RET/PTC1, inibe a fosforilação de ERK, o crescimento celular e modula a expressão de genes do ciclo celular e diferenciação. Estes dados contribuem na aplicação de terapias dirigidas a efetores das vias PI3K e MAPK no câncer de tiróide, além de salientar o envolvimento do miRNA let-7 como um gene supressor tumoral nesta doença. / In this study, we designed an assay panel for genotyping 111 mutations by mass spectrometry in RET, BRAF, NRAS, HRAS, KRAS, PIK3CA, AKT1 and other related genes in many thyroid cancer cell lines and tumors. We show that patients with BRAF and RAS mutations have distinct prognosis and that BRAF mutations are highly prevalent in metastatic thyroid cancers. Mutations of PIK3CA and AKT1, the latter not previously described in this disease, are comparatively frequent in thyroid cancers. In addition, we evaluated the role of let-7 microRNA in this cancer. We show that RET/PTC3 activation in PCCl3 thyroid cells reduces let-7 expression. Moreover, transfection of let-7 in TPC-1 cells, which harbor RET/PTC1 rearrangement, inhibits MAPK activation, reduces cell growth and modulates the expression of cell cycle and differentiation genes. These findings may contribute to the design of therapies directed at MAPK and PI3K effectors and to highlight the function of let-7 as tumor suppressor gene in thyroid cancer.